By Michael Dabaie

Regulus Therapeutics Inc. (RGLS) said Tuesday it restructured its collaboration and license agreement with Sanofi (SNY).

Regulus granted Sanofi a world-wide exclusive license to develop and commercialize its investigational drug, targeting miR-21 for all indications including Alport syndrome. Sanofi will assume all future costs and development activities for advancement of RG-012, which is currently in Phase 2 for Alport syndrome.

Regulus is eligible to receive approximately $7 million in upfront and material transfer payments and up to $40 million in development milestone payments. In addition, Sanofi will reimburse Regulus for certain out-of-pocket transition activities and assume Regulus' upstream license royalty obligations.

Shares of Regulus were up 24% at $2.33 premarket.

Alport syndrome is an inherited form of kidney disease. It represents a high unmet medical need with no approved therapy, Regulus said.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

November 06, 2018 08:38 ET (13:38 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to May 2024 Click Here for more Sanofi Charts.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Sanofi Charts.